

CORE ASSAY LIST 2008

SECONDARY PHARMACOLOGY

REF #	PROJECT TYPE	ASSAY PRINCIPLE	TURNAROUND TIME	MINIMUM COMPOUND REQUIRED	STANDARD FORMAT
PZSEP - 01	<i>In vitro</i> pharmacology, isolated tissue assay; human atrial appendage	<p>Test model: Measurement of a compound's effect on cardiac muscle contractility for early identification of compounds that adversely affect either rate of beating (chronotropism) or force of contraction (inotropism).</p> <p>Assay format: Concentration-effect curve to test compound compared to a reference compound.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1 mg	1 client compound & 1 reference compound each in 1 donor
PZSEP - 02	<i>In vitro</i> pharmacology, isolated tissue assay; human coronary artery: large	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause coronary vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1 mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor
PZSEP - 03	<i>In vitro</i> pharmacology, isolated tissue assay; human coronary artery: small, 'resistance-like'	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause cerebral vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1 mg	2 client cmpds & 1 reference compound in 1 donor
PZSEP - 04	<i>In vitro</i> harmacology, isolated tissue assay; human middle cerebral artery: large	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause cerebral vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	6 weeks After receipt of clients' compounds	2 x 1 mg	2 client compounds tested in duplicate, 1 reference compounds & 1 vehicle control in 1 donor


SECONDARY PHARMACOLOGY

REF #	PROJECT TYPE	ASSAY PRINCIPLE	 TURNAROUND TIME	MINIMUM COMPOUND REQUIRED	STANDARD FORMAT
PZSEP - 05	<i>In vitro</i> pharmacology, isolated tissue assay: human middle cerebral artery: small, 'resistance-like'	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause cerebral vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	6 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds & 1 reference compound in 1 donor
PZSEP - 06	<i>In vitro</i> pharmacology, isolated tissue assay: human bronchus: large airways	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause bronchoconstriction/bronchodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor
PZSEP - 07	<i>In vitro</i> pharmacology, isolated tissue assay: human bronchus: small airways	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause bronchoconstriction/bronchodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compounds & 1 vehicle control in 1 donor
PZSEP - 08	<i>In vitro</i> pharmacology, isolated tissue assay: human pulmonary artery: large	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause pulmonary vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compounds & 1 vehicle control in 1 donor
PZSEP - 09	<i>In vitro</i> pharmacology, isolated tissue assay: human pulmonary artery: small, 'resistance-like'	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause pulmonary vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds & 1 reference compound in 1 donor


SECONDARY PHARMACOLOGY

REF #	PROJECT TYPE	ASSAY PRINCIPLE	 TURNAROUND TIME	MINIMUM COMPOUND REQUIRED	STANDARD FORMAT
PZSEP - 10	<i>In vitro</i> pharmacology, isolated tissue assay: human subcutaneous artery: large	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause subcutaneous vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor
PZSEP - 11	<i>In vitro</i> pharmacology, isolated tissue assay: human subcutaneous artery: small, 'resistance-like'	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause subcutaneous vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds & 1 reference compound in 1 donor
PZSEP - 12	<i>In vitro</i> pharmacology, isolated tissue assay: human lower limb skeletal muscle artery: large	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause lower limb vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	6 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor
PZSEP - 13	<i>In vitro</i> pharmacology, isolated tissue assay: human lower limb skeletal muscle artery: small, 'resistance-like'	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause lower limb vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	6 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds & 1 reference compound in 1 donor
PZSEP - 14	<i>In vitro</i> pharmacology, isolated tissue assay: human renal artery: large	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause renal vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	8 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor

SECONDARY PHARMACOLOGY

REF #	PROJECT TYPE	ASSAY PRINCIPLE	 TURNAROUND TIME	MINIMUM COMPOUND REQUIRED	STANDARD FORMAT
PZSEP -15	<i>In vitro</i> pharmacology, isolated tissue assay: human renal artery: small, 'resistance-like'	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause renal vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	8 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds & 1 reference compound in 1 donor
PZSEP - 16	<i>In vitro</i> pharmacology, isolated tissue assay: human saphenous vein	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause venous vasoconstriction/vasodilatation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	8 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds , 1 reference compound & 1 vehicle control in 1 donor
PZSEP - 17	<i>In vitro</i> pharmacology, isolated tissue assay: human bladder detrusor	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause contraction/relaxation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	4 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor
PZSEP - 18	<i>In vitro</i> pharmacology, isolated tissue assay: human urethra	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause contraction/relaxation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	4 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds, 1 reference compound & 1 vehicle control in 1 donor
PZSEP - 19	<i>In vitro</i> pharmacology, isolated tissue assay: human stomach	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause contraction/relaxation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds in duplicate, 1 reference compound & 1 vehicle control in 1 donor

SECONDARY PHARMACOLOGY

REF #	PROJECT TYPE	ASSAY PRINCIPLE	 TURNAROUND TIME	MINIMUM COMPOUND REQUIRED	STANDARD FORMAT
PZSEP - 20	<i>In vitro</i> pharmacology, isolated tissue assay: human small intestine	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause contraction/relaxation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds in duplicate, 1 reference cmpd & 1 vehicle control in 1 donor
PZSEP - 21	<i>In vitro</i> pharmacology, isolated tissue assay: human large intestine	<p>Test model: Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause contraction/relaxation.</p> <p>Assay format: Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p>Data format: MS Word™ report containing analysed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds in duplicate, 1 reference cmpd & 1 vehicle control in 1 donor

For ordering and updated information go to www.asterand.com or call us at **US 313 263 0960/Europe +44 (0) 1763 211600**